Search for:

In brief

Following the issuance of the notification from the Ministry of Public Health regarding determination of category V narcotics, B.E. 2565 (2022) (the “Notification“), which we discussed in our previous client alert (link), the Thai Food and Drug Administration (FDA) has recently provided guidelines.


The recently provided guidelines are the following:

  1. The growing of cannabis or hemp plants for individual use or commercial purposes
  2. The import of cannabis or hemp parts
  3. The import of cannabis or hemp extracts under the law on narcotics
  4. The import of finished products containing cannabis or hemp parts/extracts

The guidelines will become effective on 9 June 2022.

Author

Peerapan is Head of Healthcare & Life Sciences Industry Group and a corporate and M&A partner in the Bangkok office with specialties in highly regulated industries. Within the Bangkok office, she also co-leads Japan Advisory Group. Peerapan was awarded ‘Client Choice winner’ for Healthcare & Life Sciences 2019 by Lexology. She has been consistently recognized as 'Leading Individual’ in Corporate M&A by Asia Pacific Legal 500 for eight consecutive years (2013-2020).

Author

Panyavith assists major local and multinational clients in a range of heavily regulated industries, such as healthcare & life sciences and petrochemical, on large complex mergers and acquisitions, private equity transactions, joint ventures, corporate restructurings, and post-acquisition integration projects. With his technical and commercial astute, Panyavith has often been involved in a number of pioneering projects, helping clients navigate the challenges of uncharted waters and emerging opportunities with innovative solutions.

Author

Praween Chantanakomes is a Legal Professional in Baker McKenzie, Bangkok office.

Author

Prim Uditananda is a Regulatory Affairs Manager in Baker McKenzie, Bangkok office.

Author

Parisa Nontasirichayakul is an Associate in Baker McKenzie Bangkok office.

Write A Comment